A Transcriptional Regulatory Network Model Reveals miR-34a as a Potential Regulator of Proliferation in Cancer Cell Lines
暂无分享,去创建一个
Rodrigo Mora-Rodríguez | Cristian Vargas-Mora | Man Sai Acón | Steve Quirós | M. Acon | R. Mora-Rodríguez | S. Quirós | Cristian Vargas-Mora
[1] Frances M. G. Pearl,et al. Therapeutic opportunities within the DNA damage response , 2015, Nature Reviews Cancer.
[2] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[3] J. Šmarda,et al. c-Myb regulates NOX1/p38 to control survival of colorectal carcinoma cells. , 2016, Cellular signalling.
[4] S. Berberich,et al. MicroRNA-34a Modulates MDM4 Expression via a Target Site in the Open Reading Frame , 2012, PloS one.
[5] George A. Calin,et al. microRNA Therapeutics in Cancer — An Emerging Concept , 2016, EBioMedicine.
[6] J. Barciszewski,et al. Comprehensive analysis of microRNA expression profile in malignant glioma tissues , 2015, Molecular oncology.
[7] L. Marnett,et al. Endogenous DNA damage and mutation. , 2001, Trends in genetics : TIG.
[8] M. E. Perry. The regulation of the p53-mediated stress response by MDM2 and MDM4. , 2010, Cold Spring Harbor perspectives in biology.
[9] M. Schutte,et al. Role of Mdm4 in drug sensitivity of breast cancer cells , 2010, Oncogene.
[10] D. Meek,et al. The p53 response to DNA damage. , 2004, DNA repair.
[11] A. Shiras,et al. Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways , 2014, FEBS open bio.
[12] Mudita Singhal,et al. COPASI - a COmplex PAthway SImulator , 2006, Bioinform..
[13] H. Jia,et al. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex. , 2013, Experimental cell research.
[14] Y. Ersoy,et al. p53 expression and relationship with MDM2 amplification in breast carcinomas. , 2016, Annals of diagnostic pathology.
[15] Péter Lénárt,et al. Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. , 2008, Developmental cell.
[16] V. Belyĭ,et al. The evolution of MDM2 family genes. , 2011, Gene.
[17] L. Attardi,et al. Unravelling mechanisms of p53-mediated tumour suppression , 2014, Nature Reviews Cancer.
[18] P. Conte,et al. Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. , 2016, Critical reviews in oncology/hematology.
[19] C. Peterson,et al. A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory network. , 2016, Developmental biology.
[20] D. Bernard,et al. Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment , 2014, Journal of medicinal chemistry.
[21] C. McInnes,et al. PLK1 as an oncology target: current status and future potential. , 2011, Drug discovery today.
[22] Fei Su,et al. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[23] R. Mora-Rodriguez,et al. A biocomputational platform for the automated construction of large-scale mathematical models of miRNA-transcription factor networks for studies on gene dosage compensation , 2016, 2016 IEEE 36th Central American and Panama Convention (CONCAPAN XXXVI).
[24] Wei Gu,et al. Modes of p53 Regulation , 2009, Cell.
[25] Scott W. Lowe,et al. Putting p53 in Context , 2017, Cell.
[26] B. Gallie,et al. Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma. , 2008, Biochemical and biophysical research communications.
[27] M. Fischer,et al. Census and evaluation of p53 target genes , 2017, Oncogene.
[28] Yiming Yang,et al. N-myc downstream regulated gene 1(NDRG1) promotes the stem-like properties of lung cancer cells through stabilized c-Myc. , 2017, Cancer letters.
[29] L. Tian,et al. MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. , 2014, Cancer letters.
[30] D. Lane,et al. Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.
[31] J. Bartek,et al. The DNA-damage response in human biology and disease , 2009, Nature.
[32] P. Tassone,et al. Mir-34: A New Weapon Against Cancer? , 2014, Molecular therapy. Nucleic acids.
[33] J. Lieberman,et al. miR-34 and p53: New Insights into a Complex Functional Relationship , 2015, PloS one.
[34] D. Glover,et al. Polo-like kinases: conservation and divergence in their functions and regulation , 2009, Nature Reviews Molecular Cell Biology.
[35] M. E. Perry. The Regulation of the p 53-mediated Stress Response by MDM 2 and MDM 4 , 2009 .